Nvidia slumped on a report that it’s in talks to backstop OpenAI’s next data center with its own capital. Apple set a new all-time high.

Today’s edition has the chip news, the cattle trade reversal that moved meat stocks, and everything before a massive week for earnings and the Fed.

Elon Musk’s next energy move may have nothing to do with EVs, rockets, or solar.

A new power technology, already used by the military, could help solve America’s growing energy bottleneck and reduce reliance on foreign oil. But Musk cannot build it alone.

A few little-known suppliers control key parts of the supply chain, and major tech leaders are already paying attention.

See the three “Dark Energy” stocks tied to Elon’s next energy move.

You’re looking at one consumer brand trading near its yearly high and one tiny biotech after a 112% run. Elite Trade Club Insider readers are seeing the filing details that completely change the read: one executive sale was tied to equity-compensation mechanics, while one major holder was required to return its short-swing profit to the company.

Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.

A subscription gets you:

$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.

The Wall Street Journal reported that Nvidia is in talks to provide a roughly $250 billion backstop for a massive OpenAI data-center project, raising investor concerns about circular financing — Nvidia funding OpenAI to buy Nvidia chips — and sending the stock down nearly 5% while its market cap briefly fell below Apple’s for the first time in months.

Apple hit an all-time intraday high of $339.50, with market cap reaching $4.95 trillion and briefly overtaking Nvidia as the largest U.S. company, as it approaches the $5 trillion mark ahead of Thursday’s earnings report.

Salesforce gained 7%, the Dow’s biggest mover, continuing a run of evidence that enterprise software can deliver when the numbers hold up.

The USDA announced plans to lift a more than year-long ban on Mexican cattle imports, easing supply constraints for meatpackers and sending Tyson up 7% and JBS up 10%.

Microsoft and Meta both report Wednesday, with the Fed’s rate decision on the same day — arguably the least predictable Fed meeting in years.

BioMarin and n-Lorem Foundation announced a strategic collaboration to develop a treatment for ReNU syndrome, granting BioMarin a global license to advance an investigational antisense medicine for a rare genetic neurodevelopmental condition.

The program targets a variant associated with about 75% of ReNU syndrome cases, with BioMarin leading broader development following preclinical work and lead-candidate selection. The story fits healthcare and pharma because it is a fresh rare-disease partnership, not a stock move.

Freenome received FDA approval for its SimpleScreen CRC blood test, clearing the way for Abbott to commercialize the colorectal cancer screening product in the U.S. this fall for average-risk adults 45 and older.

The approval gives Abbott another diagnostics growth lane while expanding blood-based cancer screening options for people who avoid or do not complete stool-based tests. It also puts the product into a market where earlier detection remains a major healthcare priority.

Cracker Barrel named David Deno as its next chief executive on Monday, with the former Bloomin' Brands boss taking over on August 10 from Julie Masino, who steps down and leaves the board after a turbulent stretch for the chain.

Masino had faced activist pressure and public outcry over the 2025 logo redesign and remodels that stripped away the brand's nostalgic look, a saga that drew in even President Trump before the company reversed course and kept its original image.

Philip Morris said Monday it has doubled its planned investment in its Aurora, Colorado campus to roughly $1.2 billion through 2028, expanding capacity for Zyn as it opened the newly built plant just outside Denver.

The move deepens the Marlboro maker's push away from cigarettes toward smoke-free products, coming in the weeks after the FDA authorized 20 Zyn pouches as less harmful than cigarettes, as rivals like British American Tobacco court the same fast-growing market.

Fanatics agreed to buy BGC Group assets to launch a prediction market exchange, adding federally regulated market infrastructure to its fast-growing sports platform.

The deal gives Fanatics a path beyond merchandise, collectibles, and betting, while giving BGC a divestment story tied to prediction-market demand as sports, finance, and event-based trading converge.

NBCUniversal and Google's YouTube reached a new agreement to bring Peacock to YouTube Premium subscribers in the U.S. starting in early 2027, while also extending NBC's YouTube TV carriage deal.

The partnership gives Comcast's streaming service its largest wholesale distribution agreement and puts Peacock originals, NFL games, NBA coverage, and live sports in front of YouTube's wider paid subscriber base.

Your retirement balance may be rising while inflation quietly reduces what those dollars can buy.

That is why some investors are adding physical gold and silver to their retirement plans.

Red State Gold’s free 2026 Gold IRA Guide explains how an eligible rollover may work without triggering current taxes or penalties.

Get the Free Guide and See How to Protect Your Purchasing Power.

Ford has entered the race to build the U.S. Army’s next tactical truck, securing a Defense Department contract to develop three prototypes based on its F-Series Super Duty platform.

The program puts Ford against General Motors for a vehicle designed to transport soldiers and provide mobile battlefield power, opening what Ford describes as its largest military contract opportunity since the Cold War.

Tesla’s Cybertruck is under fresh pressure after new analysis labeled the electric pickup a bigger commercial disappointment than Ford’s Edsel, with first-year sales falling far below the company’s original production ambitions.

Fewer than 40,000 Cybertrucks were sold during the first year against an annual target of 250,000, while roughly 7,100 U.S. registrations in 2026 point to fading demand for one of Tesla’s most heavily promoted vehicles.

Expand Energy agreed to buy Twin Eagle for $1.25 billion, adding a natural gas and power marketer that handles wholesale sales, storage, logistics, and analytics across North America.

The deal expands the company beyond production, giving the combined platform access to about 90% of U.S. and Canadian gas markets while lifting Expand’s expected annual marketing free cash flow to $750 million.

Alliance Resource Partners reported stronger second-quarter revenue and record royalties, with higher coal volumes and oil-and-gas mineral income helping the diversified energy company offset weaker coal pricing.

The quarter also brought 21.2 million tons of new coal commitments and a $206.2 million mineral-interest acquisition, strengthening a business that now combines coal supply with a larger royalty portfolio.

T3 Defense [DFNS] $13.10 (+201.15%)

T3 Defense executed a 1-for-125 reverse stock split effective July 20 to regain Nasdaq compliance, dramatically shrinking the public float.

Today’s 211% move reflects the kind of momentum that thin-float post-split names attract, amplified by the company’s ongoing Project35 acquisition — which positions it on both sides of drone strike and interception systems at a time when Iran war demand for defense electronics is as real as it gets.

Strong Buy rated.

Forte Biosciences [FBRX] $76.50 (+39.65%)

Forte continues to build on its Phase 1b vitiligo data from July 9 that sent the stock up nearly 80% in a single session.

The stock has now more than doubled from that announcement as the FB102 program gains institutional traction and the Phase 2 celiac disease readout approaches later in the year.

Buy rated at $1.57 billion. Good data with a clean upcoming catalyst doesn’t cool off fast.

Euda Health Holdings [EUDA] $19.00 (+26.75%)

Euda Health is a Southeast Asian digital health platform at a $47.42 million market cap running at 4.23x average volume today.

The company has been building regional health sector momentum through July, and today’s 26% move on 15K volume reflects active institutional positioning into a name with real operations across digital health delivery in Singapore and Malaysia.

MapLight Therapeutics [MPLT] $9.90 (-72.91%)

MapLight’s Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia delivered exactly the kind of mixed read that destroys the market’s confidence in a drug program.

The twice-daily dose hit the primary endpoint with a 4.5-point PANSS improvement. The once-daily dose — the commercially relevant dosing regimen patients would actually prefer — failed to achieve statistical significance.

The path to a Phase 3 just got significantly harder to map. Strong Buy rated at $1.56 billion.

Capricor Therapeutics [CAPR] $7.00 (-64.49%)

The FDA posted briefing documents ahead of Capricor’s July 29 advisory committee meeting on deramiocel for Duchenne muscular dystrophy, and the documents questioned whether the single pivotal Phase 3 trial (HOPE-3) provides sufficient evidence of effectiveness.

When the FDA signals doubt before the adcom, the market doesn’t wait for the meeting to find out how it goes. Strong Buy rated at $1.14 billion.

D. Boral ARC Acquisition [BCAR] $7.79 (-24.73%)

D. Boral ARC Acquisition Corp. III is a SPAC at a $312.32 million market cap that fell 25% today on 0.29x relative volume. SPACs in this price range face constant redemption pressure as merger timelines extend and trust value becomes the floor.

Today’s move reflects positioning adjustments ahead of any upcoming deadline or deal update.

Wall Street banks are warning that the next market crisis could be unlike anything investors have seen in decades.

If Goldman Sachs and Morgan Stanley are right, portfolios could remain under pressure for 10 years or longer.

After repeated market shocks since 2022, some experts believe the instability could continue well into the 2030s.

See How to Defend Your Portfolio Now

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.